Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer

Jian Zhang; Leiping Wang; Zhonghua Wang; Biyun Wang; Jun Cao; Fangfang Lv; Sheng Zhang; Zhimin Shao; Xichun Hu

doi:10.18632/oncotarget.18539

Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer

Oncotarget ◽

10.18632/oncotarget.18539 ◽

2017 ◽

Vol 8 (45) ◽

pp. 79527-79536 ◽

Cited By ~ 2

Author(s):

Jian Zhang ◽

Leiping Wang ◽

Zhonghua Wang ◽

Biyun Wang ◽

Jun Cao ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Low Dose ◽

Triple Negative ◽

Metastatic Breast ◽

Oral Cyclophosphamide ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

Annals of Oncology ◽

10.1093/annonc/mdy201 ◽

2018 ◽

Vol 29 (8) ◽

pp. 1763-1770 ◽

Cited By ~ 30

Author(s):

D.A. Yardley ◽

R. Coleman ◽

P. Conte ◽

J. Cortes ◽

A. Brufsky ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Triple Negative ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

A multicenter phase II study of epirubicin with low-dose trastuzumab as a first line treatment in Her-2 overexpressing metastatic breast cancer: preliminary results

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(06)80420-9 ◽

2006 ◽

Vol 4 (2) ◽

pp. 165

Author(s):

M. Zilli ◽

De Tursi ◽

C. Carella ◽

E. Ricevuto ◽

P. Marchetti ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Low Dose ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

Her 2 ◽

First Line Treatment

Download Full-text

Abstract OT2-2-01: tnAcity: A phase II/III trial ofnab-paclitaxel (nab-P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC)

10.1158/1538-7445.sabcs14-ot2-2-01 ◽

2015 ◽

Author(s):

Denise A Yardley ◽

Robert E Coleman ◽

Pierfranco Conte ◽

Joyce O'Shaughnessy ◽

Javier Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

Low-Dose Metronomic Oral Administration of Vinorelbine in the First-line Treatment of Elderly Patients With Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.3816/cbc.2010.n.039 ◽

2010 ◽

Vol 10 (4) ◽

pp. 301-306 ◽

Cited By ~ 56

Author(s):

Raffaele Addeo ◽

Alessandro Sgambato ◽

Gregorio Cennamo ◽

Liliana Montella ◽

Vincenzo Faiola ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Elderly Patients ◽

Oral Administration ◽

Low Dose ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

Tnacity: a Phase Ii/Iii Trial of Nab-Paclitaxel (Nab-P) Plus Either Gemcitabine (Gem) or Carboplatin (Carbo) Vs Gem/Carbo As First-Line Treatment for Triple-Negative Metastatic Breast Cancer (Tnmbc)

Annals of Oncology ◽

10.1093/annonc/mdu329.62 ◽

2014 ◽

Vol 25 ◽

pp. iv135

Author(s):

P.F. Conte ◽

D.A. Yardley ◽

A. Brufsky ◽

R.E. Coleman ◽

J. Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

Randomized phase II trial comparing docetaxel with or without low-dose metronomic oral cyclophosphamide in first-line treatment of non-triple-negative advanced breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.1041 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 1041-1041

Author(s):

Leiping Wang ◽

Jian Zhang ◽

Zhong Hua Wang ◽

Biyun Wang ◽

Jun Cao ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Low Dose ◽

Triple Negative ◽

Phase Ii Trial ◽

Oral Cyclophosphamide ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

P101 A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer

The Breast ◽

10.1016/s0960-9776(07)70161-3 ◽

2007 ◽

Vol 16 ◽

pp. S41

Author(s):

M. De Tursi ◽

C. Carella ◽

E. Ricevuto ◽

A. Gennari ◽

C. Orlandini ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Low Dose ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

Her 2 ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.733400528.793562861 ◽

2019 ◽

Author(s):

Sherene Loi

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Triple Negative ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

A Phase II Trial of Split, Low-Dose Docetaxel and Low-Dose Capecitabine: A Tolerable and Efficacious Regimen in the First-Line Treatment of Patients with HER2/neu–Negative Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.3816/cbc.2008.n.017 ◽

2008 ◽

Vol 8 (2) ◽

pp. 162-167 ◽

Cited By ~ 6

Author(s):

Orlando Silva ◽

Gilberto Lopes ◽

Daniel Morgenzstern ◽

Christopher Lobo ◽

Philomena Doliny ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Low Dose ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

413 POSTER A multicenter phase II study of Epirubicin (E) with low-dose herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary results

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80711-6 ◽

2005 ◽

Vol 3 (2) ◽

pp. 116

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Low Dose ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

Her 2 ◽

First Line Treatment

Download Full-text